Edgewise Therapeutics (EWTX) Retained Earnings (2020 - 2026)
Edgewise Therapeutics (EWTX) reported Retained Earnings of -$595.4 million for Q1 2026, down 170.16% on a YoY basis from $848.7 million in Q1 2025, and down 155.75% sequentially from $1.1 billion in Q4 2025.
Edgewise Therapeutics (EWTX) Retained Earnings (2020 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 7 years of Retained Earnings data on file, last reported at -$595.4 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 170.16% year-over-year to -$595.4 million; the trailing twelve-month figure through Mar 2026 stood at -$595.4 million (down 170.16% YoY), and the FY2025 full-year result was $1.1 billion, up 254171.67% from the prior year.
- Retained Earnings eased to -$595.4 million in Q1 2026, from $1.1 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.1 billion in Q4 2025 to a low of -$595.4 million in Q1 2026.
- A 5-year average of $108.7 million and a median of -$1.1 million in 2024 frame the typical range for Retained Earnings.
- Peak annual rise in Retained Earnings reached 655475.93% in 2022, while the deepest fall reached 326224.24% in 2022.
- Tracing EWTX's Retained Earnings over 5 years: stood at -$1.4 million in 2022, then surged by 107.31% to $99000.0 in 2023, then soared by 324.24% to $420000.0 in 2024, then soared by 254171.67% to $1.1 billion in 2025, then tumbled by 155.75% to -$595.4 million in 2026.
- Business Quant data shows EWTX's Retained Earnings at -$595.4 million in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Edgewise Therapeutics | 4.21 Bn | 4.21 Bn | - | -595.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -595.40 Mn |
| Dec 31, 2025 | 1.07 Bn |
| Sep 30, 2025 | 1.05 Bn |
| Jun 30, 2025 | -455.50 Mn |
| Mar 31, 2025 | 848.68 Mn |
| Dec 31, 2024 | 420,000.00 |
| Sep 30, 2024 | -338.91 Mn |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -861,000.00 |
| Dec 31, 2023 | 99,000.00 |
| Sep 30, 2023 | 505.47 Mn |
| Jun 30, 2023 | -188.90 Mn |
| Mar 31, 2023 | -167.44 Mn |
| Dec 31, 2022 | -1.36 Mn |
| Sep 30, 2022 | -125.20 Mn |
| Jun 30, 2022 | -107.69 Mn |
| Mar 31, 2022 | 353.90 Mn |
| Dec 31, 2021 | -76.96 Mn |
| Sep 30, 2021 | -64.26 Mn |
| Jun 30, 2021 | -33,000.00 |